ASTRIA THERAPEUTICS INC (ATXS) Fundamental Analysis & Valuation

NASDAQ:ATXS • US04635X1028

Current stock price

12.58 USD
+0.08 (+0.64%)
At close:
12.58 USD
0 (0%)
After Hours:

This ATXS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. ATXS Profitability Analysis

1.1 Basic Checks

  • ATXS had negative earnings in the past year.
  • In the past year ATXS has reported a negative cash flow from operations.
  • In the past 5 years ATXS always reported negative net income.
  • ATXS had a negative operating cash flow in each of the past 5 years.
ATXS Yearly Net Income VS EBIT VS OCF VS FCFATXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

  • The Return On Assets of ATXS (-45.62%) is comparable to the rest of the industry.
  • The Return On Equity of ATXS (-53.17%) is better than 65.52% of its industry peers.
Industry RankSector Rank
ROA -45.62%
ROE -53.17%
ROIC N/A
ROA(3y)-26.21%
ROA(5y)-65.84%
ROE(3y)-27.65%
ROE(5y)-70.79%
ROIC(3y)N/A
ROIC(5y)N/A
ATXS Yearly ROA, ROE, ROICATXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ATXS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ATXS Yearly Profit, Operating, Gross MarginsATXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. ATXS Health Analysis

2.1 Basic Checks

  • The number of shares outstanding for ATXS has been increased compared to 1 year ago.
  • The number of shares outstanding for ATXS has been increased compared to 5 years ago.
  • There is no outstanding debt for ATXS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ATXS Yearly Shares OutstandingATXS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
ATXS Yearly Total Debt VS Total AssetsATXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 6.54 indicates that ATXS is not in any danger for bankruptcy at the moment.
  • ATXS has a better Altman-Z score (6.54) than 76.57% of its industry peers.
  • ATXS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 6.54
ROIC/WACCN/A
WACCN/A
ATXS Yearly LT Debt VS Equity VS FCFATXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

  • ATXS has a Current Ratio of 10.78. This indicates that ATXS is financially healthy and has no problem in meeting its short term obligations.
  • ATXS has a Current ratio of 10.78. This is amongst the best in the industry. ATXS outperforms 84.95% of its industry peers.
  • ATXS has a Quick Ratio of 10.78. This indicates that ATXS is financially healthy and has no problem in meeting its short term obligations.
  • ATXS has a better Quick ratio (10.78) than 84.95% of its industry peers.
Industry RankSector Rank
Current Ratio 10.78
Quick Ratio 10.78
ATXS Yearly Current Assets VS Current LiabilitesATXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. ATXS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an nice 12.44% over the past year.
EPS 1Y (TTM)12.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 7.30% on average over the next years.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-53.66%
EPS Next 2Y-26.06%
EPS Next 3Y-11.95%
EPS Next 5Y7.3%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ATXS Yearly Revenue VS EstimatesATXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
ATXS Yearly EPS VS EstimatesATXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -50 -100 -150 -200

More info and screens

Find the best growth stocksShow best growing peers

0

4. ATXS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ATXS. In the last year negative earnings were reported.
  • Also next year ATXS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ATXS Price Earnings VS Forward Price EarningsATXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ATXS Per share dataATXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • ATXS's earnings are expected to decrease with -11.95% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-26.06%
EPS Next 3Y-11.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ATXS Dividend Analysis

5.1 Amount

  • No dividends for ATXS!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ATXS Fundamentals: All Metrics, Ratios and Statistics

ASTRIA THERAPEUTICS INC

NASDAQ:ATXS (1/22/2026, 8:23:15 PM)

After market: 12.58 0 (0%)

12.58

+0.08 (+0.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-09
Inst Owners83.38%
Inst Owner Change-0.01%
Ins Owners0.48%
Ins Owner ChangeN/A
Market Cap718.07M
Revenue(TTM)706.00K
Net Income(TTM)-124.03M
Analysts71.43
Price Target21.62 (71.86%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-16.74%
Min EPS beat(2)-38.11%
Max EPS beat(2)4.64%
EPS beat(4)2
Avg EPS beat(4)1.09%
Min EPS beat(4)-38.11%
Max EPS beat(4)56.57%
EPS beat(8)3
Avg EPS beat(8)-2.91%
EPS beat(12)6
Avg EPS beat(12)-0.93%
EPS beat(16)8
Avg EPS beat(16)-98.75%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-17.94%
EPS NQ rev (1m)13.32%
EPS NQ rev (3m)13.05%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.64%
Revenue NQ rev (1m)166.67%
Revenue NQ rev (3m)166.67%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-37.3%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1017.09
P/FCF N/A
P/OCF N/A
P/B 3.08
P/tB 3.08
EV/EBITDA N/A
EPS(TTM)-1.9
EYN/A
EPS(NY)-2.27
Fwd EYN/A
FCF(TTM)-2.11
FCFYN/A
OCF(TTM)-2.1
OCFYN/A
SpS0.01
BVpS4.09
TBVpS4.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -45.62%
ROE -53.17%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-26.21%
ROA(5y)-65.84%
ROE(3y)-27.65%
ROE(5y)-70.79%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 83.57%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.78
Quick Ratio 10.78
Altman-Z 6.54
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.44%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30.95%
EPS Next Y-53.66%
EPS Next 2Y-26.06%
EPS Next 3Y-11.95%
EPS Next 5Y7.3%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-17.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-40.43%
EBIT Next 3Y-20.11%
EBIT Next 5Y-16.07%
FCF growth 1Y-146.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-145%
OCF growth 3YN/A
OCF growth 5YN/A

ASTRIA THERAPEUTICS INC / ATXS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for ASTRIA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ATXS.


Can you provide the valuation status for ASTRIA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 0 / 10 to ASTRIA THERAPEUTICS INC (ATXS). This can be considered as Overvalued.


How profitable is ASTRIA THERAPEUTICS INC (ATXS) stock?

ASTRIA THERAPEUTICS INC (ATXS) has a profitability rating of 1 / 10.


What is the financial health of ASTRIA THERAPEUTICS INC (ATXS) stock?

The financial health rating of ASTRIA THERAPEUTICS INC (ATXS) is 8 / 10.